On the surface, the news that the Environmental Protection Agency is cracking down on carbon dioxide emissions seems like the beginning of the end for coal stocks like Peabody Energy (BTU), Walter Energy (WLT) and Arch Coal (ACI).
Top 5 Construction Companies To Watch For 2016: Steiner Leisure Limited(STNR)
Steiner Leisure Limited provides spa services and personal care products for men, women, and teenagers worldwide. The company offers beauty care products, including cleansers, toners, moisturizers, lotions, waxing products, cleansing accessories, and other skin care and body products, as well as aromatherapy oils and beauty tools; and hair care products, such as shampoos, conditioners, styling products, and related items. Its services include massages, facials, microdermabrasion, waxing, aromatherapy treatments, seaweed wraps, aerobic exercise, yoga, pilates, hair styling, manicures, pedicures, and teeth whitening, as well as various other beauty and body treatments and services; acupuncture; and medi-spa services comprising BOTOX Cosmetic, Dysport, Restylane, and Perlane. In addition, the company operates approximately 12 post-secondary schools, which provide education in massage therapy, beauty, skin care, and related areas at 30 campuses in 14 states. Further, it provid es procedures for the removal of unwanted facial and body hair in a clinical setting. The company offers its products and services under the Elemis, La Th�apie, Bliss, Rem�e, Laboratoire Rem�e, Mandara Spa, Mandara, Jou, and Chavana brands through department stores; third party retail outlets; distributors; salons; mail orders; and company owned Websites, including www.timetospa.com, www.timetospa.co.uk, www.blissworld.com, www.blisslondon.co.uk, and www.bodyworkmall.com, as well as through the QVC home shopping television channel. As of February 13, 2012, it served 152 cruise ships representing 19 cruise lines; and operated 54 resort spas, 11 urban hotel spas, 6 day spas, and 59 ideal image laser hair removal centers. Steiner Leisure Limited was founded in 1934 and is based in Nassau, the Bahamas.
Advisors' Opinion:- [By Rick Munarriz]
Royal Caribbean,�NCL (NYSE: NCL ) , and ship spa services provider Steiner Leisure (NASDAQ: STNR ) all hit new 52-week highs earlier this month. Unlike Carnival (NYSE: CCL ) -- which has been sluggish in light of several mishaps at sea since last year -- everyone seemed to view the negative instances as Carnival-specific events. Now Royal Caribbean's fire may lead folks to question booking on any cruise line in the near future.
- [By Vera Yuan]
��onsumer products and services company Steiner Leisure Ltd. (STNR) declined after the company reported its first quarter earnings. The company did not repurchase shares during the quarter despite declines in its stock price following the late 2013 announcement of a non-renewal by Celebrity Cruise Lines. In addition, the quarter reflected continued weakness in the company�� Ideal Image laser hair removal business. Later in the quarter, the company announced a 10b5-1 plan under which the company can repurchase shares according to a pre-set plan.
- [By John Udovich]
On Thursday, small cap fitness club owner Life Time Fitness, Inc (NYSE: LTM) lost some weight for investors as analysts gave the stock a workout after its Analyst Day failed to ease their concerns, meanings its worth taking a closer look at the stock along with the performance of Town Sports International Holdings, Inc (NASDAQ: CLUB)�and Steiner Leisure Ltd (NASDAQ: STNR).
Top Healthcare Equipment Companies To Invest In 2015: FibroGen Inc (FGEN)
FibroGen, Inc. (FibroGen) is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat unmet medical needs. The Company focuses in the areas of fibrosis and hypoxia-inducible factor (HIF) biology. FibroGen�� products include Roxadustat (FG-4592), which is an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs), in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and FG-3019, which is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis. The Company�� subsidiaries include FibroGen Europe Oy (FibroGen Europe) and FibroGen China Anemia Holdings, Ltd. (FibroGen China).
Roxadustat is the HIF-PH inhibitor in Phase III clinical development, which acts by stimulating the body�� natural pathway of erythropoiesis, or red blood cell production. Roxadustat represents a new paradigm for the treatment of anemia in CKD patients and offers injectable erythropoiesis stimulating agents (ESAs). 1,449 subjects have participated in 26 completed Phase I and II clinical studies for roxadustat in North America, Europe and Asia. The Company, along with its collaboration partners, Astellas Pharma Inc., (Astellas) and AstraZeneca AB,(AstraZeneca), has designed a global Phase III program to support regulatory approval of roxadustat in both NDD-CKD and DD-CKD patients in multiple geographies.
FG-3019 is the Company�� fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), a critical common element in the progression of fibrosis and associated diseases. In Phase II IPF clinical studies, FG-3019 demonstrated the stabilization of disease and, in human studies, reversal of lung fibrosis in some patients. In an open-label Phase II pancreatic cancer study of FG-3019 plus gemcitabine and erlotinib, FG-3019 demonstrated a dose-depen! dent improvement in one year survival rate. In 10 Phase I and Phase II clinical studies of FG-3019 to date involving over 340 subjects, FG-3019 has been tolerated across a range of doses studied, and there have been no dose-limiting toxicities observed as of November 13, 2014.
The Company competes with Threshold Pharmaceuticals, Inc., Gilead Sciences, Inc., Halozyme Therapeutics, Inc., Gilead Sciences, Inc., Celgene Corporation, Janssen Biotech, Inc., Johnson & Johnson, Inc., Sanofi, Novartis and Biogen Idec.
Advisors' Opinion:- [By John Udovich]
Recent IPO�FibroGen Inc (NASDAQ: FGEN) surged 22.96% today, reportedly after the journal Hepatology published the results of a workshop between the FDA and the American Association for the Study of Liver Disease (AASLD) which laid out criteria for a phase three study of a treatment for non-alcoholic steatohepatitis (NASH)���meaning its worth taking a closer look at the stock along with the performance of potential small cap or mid cap liver disease stock peers like Conatus Pharmaceuticals Inc (NASDAQ: CNAT), Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and Raptor Pharmaceutical Corp (NASDAQ: RPTP) which rose 24.35%, 10.98% and 2.02%, respectively. According to Investors Business Daily, NASH (the more serious version of fatty liver disease) is potentially an enormous market with about 6 million�US patients but the�lack of previous treatments had left it unclear how the FDA would measure success against the disease while FibroGen Inc doesn't yet have a NASH human trial in the works, it has said it hopes to start one for its lead candidate FG-3019 (its in mid-stage trials for pulmonary fibrosis and liver fibrosis due to hepatitis B infection).
Top Healthcare Equipment Companies To Invest In 2015: Vivendi SA (VIVHY.PK)
Vivendi SA (Vivendi), incorporated on December 18, 1987, is a communications and entertainment company. As of December 31, 2009, the Company had six business segments: Activision Blizzard, Universal Music Group, SFR, Maroc Telecom Group, GVT (Holding) S.A. (GVT) and Canal+ Group. Activision Blizzard develops, publishes and distributes interactive entertainment software, online or on other media (such as console and personal computer (PC)). Universal Music Group is engaged in the sale of recorded music (physical and digital media), exploitation of music publishing rights, as well as artist services and merchandising. SFR is engaged in the phone services (mobile, broadband Internet and fixed) in France. Maroc Telecom Group is a telecommunication operator (mobile, fixed and Internet) in Africa, principally in Morocco, as well as in Mauritania, Burkina Faso, Gabon and Mali. GVT is a Brazilian fixed and broadband operator. Canal+ Group is engaged in publishing and distribution of pay-television mainly in France, in both analog and digital (terrestrially, via satellite or ADSL), as well as film production in Europe. In July 2013, Vivendi SA and Universal Music Group announced the completion of the sale of Parlophone Label Group to Warner Music Group Corp.
On November 13, 2009, Vivendi acquired an aggregate of 29.9% of GVT�� outstanding voting shares from Swarth Investments LLC, Swarth Investments Holdings LLC and Global Village Telecom (Holland) BV. In addition, Vivendi acquired from third parties an additional 8% interest in GVT's outstanding shares. On December 28, 2009, Canal+ Group, Vivendi�� subsidiary, acquired TF1�� 9.9% interest in the capital of Canal+ France. On July 31, 2009, Maroc Telecom acquired 51% controlling interest in Sotelma. On August 27, 2009, CID, a company 40% owned by SFR and 60% by other financial investors, acquired the 62% interest in 5 sur 5.
Advisors' Opinion:- [By Eric Rodawig]
Activision Blizzard (ATVI) is the world's largest and most successful video game developer, and is majority owned (61%) by French telecom and media conglomerate Vivendi (VIVHY.PK). Vivendi has been undergoing a massive strategic review with the intent to reduce debt and unlock the value of its assets that has fueled speculation surrounding ATVI. In conjunction with this, ATVI CFO Dennis Durkin announced on the 4Q12 earnings call
- [By Mike Arnold]
I normally don't look at charts much, but comparing Orange to its competitors in the French telecommunications market is quite fascinating. As one can see, incumbents Bouygues (BOUYF.PK) and Vivendi (VIVHY.PK) (owner of SFR) saw similar price declines. The market, on the other hand, rapidly bid up the price of new entrant Iliad SA (ILIAF.PK), as a result of forecasts for Iliad to capture significant mobile market share (which it did, around 10%). The wide divergence in price relative to changes in underlying value favor going long the incumbents, including Orange. Because this time it's different.
Top Healthcare Equipment Companies To Invest In 2015: American Science and Engineering Inc.(ASEI)
American Science and Engineering, Inc., together with its subsidiaries, develops, manufactures, markets, and sells X-ray inspection and other detection products for detection and security screening solutions in the United States and internationally. It offers cargo inspection systems comprising non-intrusive inspection products, which are primarily used for the screening of trucks, cars, cargo containers, pallets, and air cargo at border crossings, seaports, military bases, airports, and cargo and transportation hubs. The cargo inspection systems include OmniView gantry system, a cargo and vehicle inspection system; Z Portal system, a drive-through inspection system for scanning cargo and vehicles; Z Gantry system, a Z Backscatter inspection system for scanning cars, vans, trucks, and their cargo; Sentry Portal system, a drive through transmission X-ray inspection system; and MobileSearch High-Energy, a mobile inspection system for scanning trucks, cargo containers, and ve hicles. The company also provides Z Backscatter systems, including Z Backscatter Van, a mobile X-ray screening system to produce photo-like images of plastic explosives or other anomalies; and ZBV Military Trailer, a rugged X-ray screening system built on military trailer. In addition, it offers parcel and personnel screening inspection system that comprises Gemini system, a parcel and baggage inspection system; and SmartCheck system, a personnel screening system for screening threats hidden under a person?s clothing. Further, the company provides contract research and development programs for agencies of the United States government; and maintenance, warranty, engineering, and training services. It serves authorities responsible for port and border security, customs agencies, military organizations, high threat commercial and government facilities, aviation security agencies, and law enforcement agencies. The company was founded in 1958 and is headquartered in Billerica, M assachusetts.
Advisors' Opinion:- [By Seth Jayson]
American Science & Engineering (Nasdaq: ASEI ) is expected to report Q4 earnings on May 7. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict American Science & Engineering's revenues will grow 27.4% and EPS will expand 280.0%. - [By Rich Smith]
An unidentified "government agency" has awarded American Science & Engineering (NASDAQ: ASEI ) a $60 million contract to supply X-ray inspection systems, the company (partially) revealed Tuesday.
Top Healthcare Equipment Companies To Invest In 2015: Nordson Corporation(NDSN)
Nordson Corporation manufactures equipment used for precision dispensing, testing and inspection, and surface preparation and curing. Its Adhesive Dispensing Systems segment manufactures equipment for applying adhesives, lotions, and liquids to disposable products; automated adhesive dispensing systems for the food and beverage, and packaged goods industries; hot melt and cold glue adhesive dispensing systems for the paper and paperboard converting industries; adhesive and sealant dispensing systems for bonding or sealing plastic, metal, and wood products; and laminating and coating systems to manufacture continuous-roll goods in the nonwovens, textile, paper, and flexible-packaging industries. The company?s Advanced Technology Systems segment comprises automated gas plasma treatment systems used to clean and condition surfaces for the semiconductor, medical, and printed circuit board industries; controlled manual and automated systems for applying materials in customer pr ocesses requiring precision and material conservation; ultraviolet equipment used in curing and drying operations for specialty coatings, semiconductor materials, and paints; and bond testing and automated optical and x-ray inspection systems used in the semiconductor and printed circuit board industries. Its Industrial Coating Systems segment provides automated and manual dispensing systems used for applying coatings, paint, finishes, sealants, and other materials. Nordson Corporation markets its products in the United States and internationally through a direct sales force, as well as through qualified distributors and sales representatives. It serves various markets, including the appliance, automotive, bookbinding, container, converting, electronics, food and beverage, furniture, life sciences and medical, metal finishing, non woven, packaging, and semiconductor industries. The company was founded in 1935 and is headquartered in Westlake, Ohio.
Advisors' Opinion:- [By Travis Hoium]
What: Shares of industrial product manufacturer Nordson (NASDAQ: NDSN ) dropped as much as 10% today after the company reported fiscal second-quarter earnings.
Top Healthcare Equipment Companies To Invest In 2015: The Medicines Company(MDCO)
The Medicines Company, a pharmaceutical company, provides various medicines to hospitals for advancing the treatment of critical care patients worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty and for use in patients undergoing percutaneous coronary intervention; and Cleviprex, an intravenous small molecule calcium channel blocker for the reduction of blood pressure, as well as to treat neurocritical care and cardiac surgery patients. Its products under development include Cangrelor that is in Phase III clinical trial acts as an intravenous small molecule antiplatelet agent to prevent platelet activation and aggregation; and Oritavancin, which is in Phase III clinical trial acts as an investigational intravenous antibiotic for the treatment of serious gram-positive bacterial infections, including acute bacterial skin and skin structure infections. The company?s products under development also comprise MDCO-157, a pre-registration stage product for platelet inhibition in patients suffering from acute coronary syndrome (ACS), and patients experiencing myocardial infarction, stroke, or peripheral arterial disease; MDCO-2010, a small molecule serine protease inhibitor that is in Phase II clinical trial used for the reduction of blood loss during surgery; and MDCO-216, which is in Phase I clinical trial used for the reversal of atherosclerotic plaque development and the reduction of the risk of coronary events in patients with ACS. Its products also consist of Argatroban, a direct thrombin inhibitor used as anticoagulant for prophylaxis or for the treatment of thrombosis; and acute care generic products. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.
Advisors' Opinion:- [By Jonas Elmerraji]
We're seeing the exact same price setup in shares of small-cap pharmaceutical name The Medicines Co. (MDCO) this week. Just like Gerdau, MDCO has spent the last several months trading in a descending triangle setup; the key difference here is that this trade hasn't triggered yet. The sell signal comes in on a break below support down at $24.
Why all of the significance at $24? It's not magic. Whenever you're looking at any technical price pattern, it's critical to keep buyers and sellers in mind. Patterns like the descending triangle are a good way to quickly describe what's going on in a stock, but they're not the reason it's tradable. Instead, it all comes down to supply and demand for shares.
That $24 level in MDCO is the spot where there's previously been an excess of demand for shares; in other words, it's a price where buyers have been more eager to step in and buy shares at a lower price than sellers were to sell. That's what makes a breakdown below support so significant -- the move means that sellers are finally strong enough to absorb all of the excess demand at the at price level. While MDCO could still have some upside in the near-term and stay within the triangle, it's a name best avoided this summer.
Read More: Trade These 5 Consumer Stocks for Gains in August
- [By Rich Duprey]
If all goes well in phase 3�trials for�ProFibrix's lead biologic, Fibrocaps -- a treatment�to stop bleeding during surgery -- shareholders of the Netherlands-based drugmaker could receive a hefty payday from The Medicines Company (NASDAQ: MDCO ) , which says it's willing to buy out the company if it can expect to bring the therapy to market here at home as well as in Europe.
No comments:
Post a Comment